Great Novel Therapeutics Biotech & Medicals (TPEX:7427)
Taiwan
· Delayed Price · Currency is TWD 40.10
-0.80 (-1.96%)
Apr 29, 2026, 1:58 PM CST
TPEX:7427 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 1.21 | 1.69 | 4.85 | 0.54 | 0.63 | Upgrade
|
| Revenue Growth (YoY) | -28.49% | -65.26% | 798.15% | -14.29% | - | Upgrade
|
| Cost of Revenue | 2.39 | 0.67 | 0.04 | 0.08 | 0.35 | Upgrade
|
| Gross Profit | -1.18 | 1.02 | 4.81 | 0.46 | 0.28 | Upgrade
|
| Selling, General & Admin | 26.35 | 28.57 | 17.5 | 19.37 | 17.7 | Upgrade
|
| Research & Development | 72.02 | 85.09 | 53.13 | 49.89 | 19.11 | Upgrade
|
| Operating Expenses | 98.36 | 113.66 | 70.63 | 69.26 | 36.8 | Upgrade
|
| Operating Income | -99.54 | -112.65 | -65.82 | -68.79 | -36.52 | Upgrade
|
| Interest Expense | -0.1 | -0.13 | -0.09 | - | - | Upgrade
|
| Interest & Investment Income | 8.02 | 7.79 | 5.33 | 0.94 | 0.52 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.06 | -0.54 | 0.33 | 0.13 | Upgrade
|
| Other Non Operating Income (Expenses) | -5.85 | 0 | 0 | 0.39 | 0.02 | Upgrade
|
| EBT Excluding Unusual Items | -97.47 | -104.92 | -61.12 | -67.13 | -35.86 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 0.12 | - | - | Upgrade
|
| Pretax Income | -97.47 | -104.92 | -61 | -67.13 | -35.86 | Upgrade
|
| Net Income | -97.47 | -104.92 | -61 | -67.13 | -35.86 | Upgrade
|
| Net Income to Common | -97.47 | -104.92 | -61 | -67.13 | -35.86 | Upgrade
|
| Shares Outstanding (Basic) | 43 | 41 | 36 | 24 | 21 | Upgrade
|
| Shares Outstanding (Diluted) | 43 | 41 | 36 | 24 | 21 | Upgrade
|
| Shares Change (YoY) | 4.63% | 13.60% | 50.23% | 14.54% | 33.09% | Upgrade
|
| EPS (Basic) | -2.26 | -2.55 | -1.68 | -2.78 | -1.70 | Upgrade
|
| EPS (Diluted) | -2.26 | -2.55 | -1.68 | -2.78 | -1.70 | Upgrade
|
| Free Cash Flow | -87.84 | -78.96 | -57.92 | -77.21 | -33.96 | Upgrade
|
| Free Cash Flow Per Share | -2.04 | -1.92 | -1.60 | -3.20 | -1.61 | Upgrade
|
| Gross Margin | -98.26% | 60.24% | 99.11% | 85.93% | 44.92% | Upgrade
|
| Operating Margin | -8260.91% | -6685.28% | -1357.11% | -12739.07% | -5796.98% | Upgrade
|
| Profit Margin | -8089.05% | -6226.94% | -1257.67% | -12431.85% | -5691.59% | Upgrade
|
| Free Cash Flow Margin | -7289.46% | -4685.82% | -1194.21% | -14298.70% | -5389.68% | Upgrade
|
| EBITDA | -91.86 | -108.62 | -63.22 | -67.03 | -35.08 | Upgrade
|
| D&A For EBITDA | 7.68 | 4.03 | 2.6 | 1.76 | 1.44 | Upgrade
|
| EBIT | -99.54 | -112.65 | -65.82 | -68.79 | -36.52 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.